Phase 2 Rheumatoid Arthritis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years old or older (or the legal age of consent in the country where the study is taking place) at the time of signing the consent form.
• People who have been diagnosed with rheumatoid arthritis (RA) according to recognised international classification standards, with the condition present for at least 3 months.
• People whose RA falls within a certain range of physical function, classified as ACR Class I to III based on 1991 criteria (confirm with trial site).
• People with moderate-to-severely active RA, measured using a specific disease activity score called DAS28-ESR above 3.2 (confirm with trial site).
• People who have had to stop a standard first-line RA medication because it did not work well enough or caused intolerable side effects.
• People who are using contraception in line with local regulations for clinical study participants.

Who may not be able to join:

• People who have recently used certain immune-suppressing medications, including JAK inhibitors (such as tofacitinib) within 4 weeks, B-cell depleting agents (such as anti-CD20 therapies) without evidence of B-cell recovery, anakinra within 1 week, abatacept within 8 weeks, TNF inhibitors within 2 to 8 weeks, cyclophosphamide within 6 months, or cyclosporine, azathioprine, mycophenolate mofetil, or leflunomide within 4 weeks of the study start date.
• People whose previous treatment with a biological IL-6 blocking medication failed due to it not working, causing intolerable side effects, or being medically unsuitable for them (though stopping an IL-6 treatment for unrelated reasons at least 3 months before the study start may not be disqualifying — confirm with trial site).
• People who are on methotrexate at a dose that has not been stable.
• People currently taking systemic corticosteroids (steroid tablets or injections) at a dose of more than 10 mg per day.
• People who are pregnant or breastfeeding.
• People who have active tuberculosis (TB) or a history of TB that was not fully treated.
• People who have had a serious infection caused by certain fungi, bacteria, or viruses, including conditions such as histoplasmosis, candidiasis, aspergillosis, or a brain condition called progressive multifocal leukoencephalopathy, even if it has resolved.
• People with diabetes that is not well controlled.
• People who have had an infection in a joint or an artificial joint in the past.
• People with a current or past history of cancer (within the past 5 years), including blood cancers, except for certain treated skin cancers or treated cervical pre-cancer.
• People with a history of inflammatory bowel disease, severe diverticulitis, or a previous tear or rupture in the digestive tract.
• People who have a history of juvenile idiopathic arthritis or whose arthritis began before the age of 16.
• People with severe, body-wide forms of RA, including conditions such as vasculitis, pulmonary fibrosis, or Felty's syndrome.

Important: Always verify eligibility with the trial site directly before applying.